Results 181 to 190 of about 8,024,802 (308)

RTHistory: An automated tool for the extraction and presentation of radiotherapy course history for continuity of care applications

open access: yesJournal of Applied Clinical Medical Physics, Volume 27, Issue 11, November 2026.
Abstract Background Transfer of radiation treatment records is a common task for radiotherapy clinics, as treatment history impacts future treatment planning, including prescription dose, fractionation, and normal tissue constraint selections. Currently, gathering radiation records relies on manual searches within treatment planning databases and ...
Justin B. Hink   +6 more
wiley   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

Metabolic Reprogramming in Glioblastoma Stem Cells Promotes Radiation Resistance Through a H3K18la/USP30/MBOAT2 Axis

open access: yesAdvanced Science, Volume 13, Issue 61, 3 November 2026.
LDHA‐driven lactate production in mesenchymal glioma stem cells promotes p300‐dependent H3K18 lactylation, activates USP30 transcription, and stabilizes MBOAT2 to remodel phosphatidylethanolamines toward ferroptosis‐resistant PE‐MUFA species. Disrupting this metabolic–epigenetic–lipid circuit enhances ferroptosis and sensitizes glioblastoma to ...
Zong Miao   +13 more
wiley   +1 more source

Treatment of a primary cardiac angiosarcoma with stereotactic body radiation therapy

open access: yesHellenic Journal of Cardiology, 2023
Anastasia Stergioula, Evaggelos Pantelis
doaj   +1 more source

Multicenter Retrospective Study of the Impact of Localized Therapy on Prognosis in Patients With Oligometastatic Solid Tumors

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Local therapy has recently been applied to treat oligometastatic cancer across various malignant cancers. However, definitive evidence for local treatment regimens remains lacking. We aimed to evaluate the clinical outcomes of combining local therapy with systemic treatment for patients with oligometastatic solid tumors including ...
Xueman Deng   +6 more
wiley   +1 more source

Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Neoadjuvant therapy has become an integral component of the multidisciplinary management of resectable non–small cell lung cancer (NSCLC). The introduction of immune checkpoint inhibitors (ICIs) has transformed the perioperative treatment landscape by improving pathological response rates, reducing the risk of recurrence, and offering the ...
Hao An   +15 more
wiley   +1 more source

Opportunities and Challenges in FLASH Radiotherapy: Focusing on Normal Tissue Protection Effects and Clinical Translation Bottleneck

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT FLASH radiotherapy (FLASH‐RT) has garnered significant attention for its “FLASH effect”, which selectively protects normal tissues while maintaining tumor‐killing efficacy at ultra‐high dose rates (UHDR). This technology represents a promising but still investigational therapeutic strategy in radiation oncology.
Xuan‐Lu He   +10 more
wiley   +1 more source

An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma

open access: yesCurrent Protocols, Volume 6, Issue 11, November 2026.
Abstract Glioblastoma (GBM) is the most lethal primary brain tumor in adults, and despite intensive research efforts, effective therapeutic breakthroughs remain elusive. Consequently, the standard of care has remained largely unchanged for nearly 30 years, underscoring the need for robust preclinical models to evaluate experimental therapies.
Julian Hübner   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy